This overlooked obesity-drug stock has 80% upside, JPMorgan says

Reuters

• Structure Therapeutics is an overlooked stock that could surge on the GLP-1 weight loss craze.
• JPMorgan initiated the company at "Overweight" with a $65 price target, representing 80% potential upside.
• "Meaningful upside from even a small piece of unprecedentedly large GLP-1 market," JPMorgan said.

The burgeoning GLP-1 weight loss market is expected to be worth $100 billion by 2030, leaving plenty of room for more companies to enter the space...